Midkine: A Novel and Early Biomarker of Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Interventions

Małyszko, Jolanta; Bachórzewska−Gajewska, Hanna; Koc-Żórawska, Ewa; Małyszko, J.; Kobus, Grażyna; Dobrzycki, Sławomir

doi:10.1155/2015/879509

Cited by 26 publications

(17 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar to our findings Malyszko et al states a positive correlation between MK and SBP. 30 In summary of our study a significant relationship between MK rise in the patients with hypertension and cognitive decrease was observed. MK levels showed a negative correlation with MMSE in hypertension patients.…”

supporting

confidence: 51%

Hipertansif Hastalarda Kognitif Fonksiyonların Değerlendirilmesi ve Serum Midkine Düzeyleriyle İlişkisi

Güzel¹,

Cinemre²,

Güzel³

et al. 2017

Sakarya Medical Journal

View full text Add to dashboard Cite

Objective: Hypertension (HT) is one of the risk factors associated with dementia. Our aim was to research cognitive functions in patients with HT and its relationship to midkine levels in serum. Material and Methods: This study examined 45 patients who were over 60 years of age, had at least five years of education, and had an essential HT diagnosis. We also had 30 healthy control subjects. The Mini Mental State Examination (MMSE) was applied to the patients. Scores of 24 and lower from the MMSE indicated a cognitive disorder. In relation serum levels of midkine were also evaluated. Results: The MMSE scores of the HT patients were compared to the control group and were significantly lower (p<0.01). Midkine levels in the HT patients (25.10 ±8.16 ng/mL) compared to the control group (19.59±7.53 ng/mL) and were significantly higher (p< 0.01). Midkine levels were also higher in HT patients with cognitive impairment compared to HT patients without any cognitive impairment (p<0.05). A significant negative correlation was observed between midkine levels and MMSE scores, (r = 0.558, p<0.01). Conclusion: This study has demonstrated an important relationship between increased serum midkine levels and cognitive decline in HT patients.

show abstract

supporting

confidence: 51%

Hipertansif Hastalarda Kognitif Fonksiyonların Değerlendirilmesi ve Serum Midkine Düzeyleriyle İlişkisi

Güzel¹,

Cinemre²,

Güzel³

et al. 2017

Sakarya Medical Journal

View full text Add to dashboard Cite

show abstract

“…Midkine (MK) is a multifunctional heparin-binding growth factor, induced by oxidative stress through activation of hypoxia-inducible factor-1a, and has been implicated in the pathogenesis of AKI and diabetic nephropathy. Investigation of MK as a renal biomarker has been undertaken with respect to contrast induced-AKI in patients undergoing percutaneous coronary intervention due to stable angina, using the iso-osmolar contrast agent iodixanol [128]. It was observed that MK was significantly higher in patients with CI-AKI.…”

Section: Midkinementioning

confidence: 99%

The ischemic/nephrotoxic acute kidney injury and the use of renal biomarkers in clinical practice

Andreucci

Faga

Pisani

et al. 2017

European Journal of Internal Medicine

100

View full text Add to dashboard Cite

The term Acute Renal Failure (ARF) has been replaced by the term Acute Kidney Injury (AKI). AKI indicates an abrupt (within 24-48h) decrease in Glomerular Filtraton Rate, due to renal damage, that causes fluid and metabolic waste retention and alteration of electrolyte and acid-base balance. The renal biomarkers of AKI are substances or processes that are indicators of normal or impaired function of the kidney. The most used renal biomarker is still serum creatinine that is inadequate for several reasons, one of which is its inability to differentiate between hemodynamic changes of renal function ("prerenal azotemia") from intrinsic renal failure or obstructive nephropathy. Cystatin C is no better in this respect. After the description of the pathophysiology of "prerenal azotemia" and of Acute Kidney Injury (AKI) due to ischemia or nephrotoxicity, the renal biomarkers are listed and described: urinary NAG, urinary and serum KIM-1, serum and urinary NGAL, urinary IL-18, urinary L-FABP, serum Midkine, urinary IGFBP7 and TIMP2, urinary α-GST and π-GST, urinary ɣGT and AP, urinary βM, urinary RBP, serum and urinary miRNA. All have been shown to appear much earlier than the rise of serum Creatinine. Some of them have been demonstrated to predict the clinical outcomes of AKI, such as the need for initiation of dialysis and mortality.

show abstract

“…143 It was believed that superoxide anions produced during the IRI procedure led to the upregulation of MK, and it is feasible that MK expression could be altered during CI-AKI. Malyszko et al 145 investigated whether MK could represent an early biomarker of CI-AKI in 89 patients with normal serum creatinine levels, who underwent PCI for angina, using the iso-osmolar CM iodixanol. Serum MK was evaluated before and 2 hours, 4 hours, 8 hours, 24 hours, and 48 hours after the administration of the radiocontrast medium; serum creatinine was assessed before and 24 hours and 48 hours after CM injection.…”

mentioning

confidence: 99%

The potential use of biomarkers in predicting contrast-induced acute kidney injury

Andreucci¹,

Faga²,

Riccio³

et al. 2016

IJNRD

View full text Add to dashboard Cite

Contrast-induced acute kidney injury (CI-AKI) is a problem associated with the use of iodinated contrast media, causing kidney dysfunction in patients with preexisting renal failure. It accounts for 12% of all hospital-acquired kidney failure and increases the length of hospitalization, a situation that is worsening with increasing numbers of patients with comorbidities, including those requiring cardiovascular interventional procedures. So far, its diagnosis has relied upon the rise in creatinine levels, which is a late marker of kidney damage and is believed to be inadequate. Therefore, there is an urgent need for biomarkers that can detect CI-AKI sooner and more reliably. In recent years, many new biomarkers have been characterized for AKI, and these are discussed particularly with their use in known CI-AKI models and studies and include neutrophil gelatinase-associated lipocalin, cystatin C (Cys-C), kidney injury molecule-1, interleukin-18, N-acetyl-β-d-glucosaminidase, and L-type fatty acid-binding protein (L-FABP). The potential of miRNA and metabolomic technology is also mentioned. Early detection of CI-AKI may lead to early intervention and therefore improve patient outcome, and in future any one or a combination of several of these markers together with development in technology for their analysis may prove effective in this respect.

show abstract

Midkine: A Novel and Early Biomarker of Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Interventions

Cited by 26 publications

References 25 publications

Hipertansif Hastalarda Kognitif Fonksiyonların Değerlendirilmesi ve Serum Midkine Düzeyleriyle İlişkisi

Hipertansif Hastalarda Kognitif Fonksiyonların Değerlendirilmesi ve Serum Midkine Düzeyleriyle İlişkisi

The ischemic/nephrotoxic acute kidney injury and the use of renal biomarkers in clinical practice

The potential use of biomarkers in predicting contrast-induced acute kidney injury

Contact Info

Product

Resources

About